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Summary
Histological transformation (HT) is a major cause of morbidity and
mortality in patients with indolent non-Hodgkin lymphoma (NHL). The
multicentre National Cancer Comprehensive Network database for NHL
provides a unique opportunity to investigate the natural history of HT in
the rituximab era. 118 patients with biopsy-confirmed indolent lymphoma
and subsequent biopsy-confirmed HT were identified. Treatments for HT
included autologous stem-cell transplant (auto-SCT) (n = 50), allogeneic
SCT (allo-SCT) (n = 18), and treatment without transplant (n = 50). The
2-year overall survival (OS) for the entire cohort was 68%. For auto-SCT
patients aged ≤60 years (n = 24), the 2-year OS was 74%. For non-
transplanted patients aged ≤60 years (n = 19), the 2-year OS was 59%. The
2-year OS of patients na€ıve to chemotherapy prior to HT was superior to
patients who were exposed to chemotherapy prior to HT (100% vs. 35%,
P = 003). In this largest prospective cohort of patients of strictly defined
HT in the rituximab era, the natural history of HT appears more favour-
able than historical studies. Younger patients who were not exposed to
chemotherapy prior to HT experienced a prolonged survival even without
transplantation. This study serves as a benchmark for future trials of novel
approaches for HT in the Rituximab era.
Keywords: rituximab era, non-Hodgkin lymphoma, histological transfor-
mation, stem-cell transplantation, diffuse large B-cell lymphoma.
The natural history of indolent non-Hodgkin lymphoma
(NHL) is variable, but generally characterized by prolonged
survival that has been recently increasing since the introduc-
tion of rituximab as part of standard therapy (Fisher et al,
2005a; Swenson et al, 2005). A major cause of morbidity and
mortality of indolent NHL is histological transformation
(HT), which is the evolution of indolent NHL to diffuse
large B-cell lymphoma (DLBCL). Transformation occurs at a
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rate of approximately 3% per year, and arises from all
subtypes of indolent B cell lymphoproliferative disorders
(Bastion et al, 1997; Al-Tourah et al, 2008). In the pre-
Rituximab era, the prognosis of transformation was generally
poor, with a median survival after histological conversion of
approximately 1 year for patients with follicular lymphoma
(FL) (Montoto et al, 2007).
For younger patients with a favourable performance sta-
tus, high-dose therapy with autologous stem cell transplan-
tation (auto-SCT) results in a prolonged progression-free
survival (PFS) for a substantial subset of patients with
transformed NHL, based upon retrospective single and
multi-institutional experiences (Bernstein & Burack, 2009).
Auto-SCT has offered 2-year overall survival (OS) rates
ranging between 40% and 74% (Foran et al, 1998;
Friedberg et al, 1999; Chen et al, 2001; Williams et al, 2001;
Andreadis et al, 2005; Sabloff et al, 2007; Ramadan et al,
2008; Eide et al, 2011). Data on the impact of rituximab on
outcome of transformation are quite limited. A preliminary
presentation of an experience of patients with HT from
Vancouver, British Columbia suggested that R-CHOP (rit-
uximab, cyclophosphamide, doxorubicin, vincristine, pred-
nisolone) results in a superior OS compared to CHOP
(cyclophosphamide, doxorubicin, vincristine, prednisolone)
for treatment of HT (Al-Tourah et al, 2007). Bains et al
(2013) studied outcomes in 34 patients with limited-stage
FL treated with radiotherapy who developed HT. They
found that the addition of rituximab for the treatment of
HT improved the 3-year post-transformation OS compared
with combination chemotherapy alone (87% vs. 385%,
P < 000001).
We used the multicentre National Cancer Comprehensive
Network (NCCN) prospective registry to define the progno-
sis of HT in the rituximab era. In this study, we describe the
experience of 118 patients with transformed lymphoma in
the rituximab era. Survival outcomes for various treatment
modalities including stem cell transplant (autologous, alloge-
neic, or both), standard chemotherapy without transplant,
and other more conservative measures were examined.
Finally, for the patients who were not transplanted for HT,
we compared the outcomes of those who were treatment-
na€ıve prior to HT versus those who were treatment-exposed
prior to HT.
Patients and methods
We used the NCCN NHL database (http://www.nccn.org/
network/business_insights/outcomes_database/outcomes.asp),
a multicentre prospective registry of comprehensive clinical,
treatment, and outcome data for patients with NHL, to eval-
uate the natural history of HT (LaCasce et al, 2008). All
patients with indolent NHL or HT presenting to participat-
ing NCCN centres between 1 July 1 2000 and 29 February
2011, were eligible for inclusion in this cohort. Patients were
identified based on transformation, and included both newly
and previously diagnosed NHL. Some of the patients were
enrolled prior to HT. The seven participating NCCN mem-
ber institutions included: City of Hope Comprehensive Can-
cer Center, Dana-Farber Cancer Center, Fox Chase Cancer
Center, Robert H. Lurie Comprehensive Cancer Center of
Northwestern University, Roswell Park Cancer Institute, The
University of Texas M.D. Anderson Cancer Center, and
The University of Michigan Comprehensive Cancer Center.
The institutional review boards at all participating centres
approved the data collection protocol for the NCCN-NHL
outcomes database.
Patients were required to meet the following definition of
HT for inclusion: (i) confirmed documentation of initial
pathological diagnosis of indolent NHL, and (ii) biopsy
proven transformation to DLBCL more than 6 months from
the initial diagnosis of the indolent histology. We required a
minimum of 6 months between the diagnosis of indolent
and aggressive histologies in order to ensure that the study
excluded composite and discordant histologies. All pathology
was reviewed at NCCN institutions by experienced haemat-
opathologists. Patients not meeting these criteria were
excluded, as were those with discordant histologies on pre-
sentation. Furthermore, patients with grade 3b FL were
excluded. Eligible patients were divided into the following
groups, based upon their treatment for histological transfor-
mation: any stem cell transplant (SCT) and no SCT for treat-
ment of HT. Patients who had SCT prior to HT were not
included. Patients who received SCT for HT were further
subdivided into autologous (auto-SCT) and allogeneic stem
cell transplant (allo-SCT). If more than one SCT was
received during follow up, type of first transplant received
following HT was used for classification. Patients in the allo-
SCT group never received auto-SCT. Primary comparisons
were made between patients who received SCT versus those
who did not (no-SCT). Subgroup analyses were performed
on the cohort of patients aged ≤60 years. Baseline demo-
graphic and clinical characteristics were examined, including:
age at initial diagnosis, age at HT, gender, ethnicity, disease
histology at diagnosis, type of therapy received prior to HT
as well as number of therapy lines prior to HT and time
from initial diagnosis to HT. For patients not receiving SCT,
type of therapy received for HT was reported. The primary
endpoint sought was OS, defined as time from HT to death.
Median follow-up time was defined as the time (in years)
starting from the diagnosis of HT to their last quality visit
date with an NCCN institution, using a reverse censoring
method. Baseline demographic and clinical characteristics
were compared between any SCT and no-SCT cohorts, auto-
SCT and allo-SCT cohorts, and auto-SCT versus allo-SCT
versus no-SCT cohorts using chi-square or Fisher’s exact test
for categorical variables and Kruskal-Wallis test for medians.
OS was estimated using the Kaplan-Meier method. P values
< 005 were considered statistically significant. All analyses
were performed using SAS v92 (SAS Institute Inc., Cary,
NC, USA).
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Results
Clinical characteristics
A total of 118 patients were eligible for analysis after exclu-
sion. Their clinical characteristics are outlined in Table I. 71
(60%) were male and the median age at diagnosis of HT was
59 years (range: 37 ~ 88 years). Histologies at diagnosis of
indolent lymphoma were: 102 (86%) FL (grades 1 ~ 3a, 3
not otherwise specified [NOS], or NOS); 12 (10%) marginal
zone lymphoma; and 4 (3%) small lymphocytic lymphoma.
Prior to HT, 23 (19%) were treatment-na€ıve while 95 (81%)
had been exposed to treatment for their indolent lymphoma.
83 (70%) were treated with rituximab-containing regimens
and 60 (51%) were exposed to anthracyclines. Median num-
ber of therapeutic lines given prior to HT was one (range
0–8). Median time from indolent NHL to HT was
30 months (range: 6–184 months).
Treatments for histological transformation
Treatment modalities for HT included auto-SCT (n = 50),
allo-SCT (n = 18), and treatment without transplant
(no-SCT; n = 50). Clinical characteristics of the patients trea-
ted with SCT for HT (n = 68) are depicted in Table II. At
the time of transplant, 78% of auto-SCT and 67% of allo-
SCT patients demonstrated a response to salvage treatment
prior to their transplant. Patients in the auto-SCT group
were older compared to the allo-SCT group (60 vs. 52 years,
P < 00001).
Clinical characteristics and treatments for HT of patients
not treated with transplant for HT are depicted in
Table III. 88% of these patients underwent chemotherapy
at HT, of which an R-CHOP-based regimen was the most
commonly used (56%). A salvage regimen (cytarabine- or
platinum-based) was used in 19 (38%), a lenalidomide-
based regimen was used in 2 (4%), and radioimmunother-
apy was administered in 3 (6%). Six (12%) patients had
neither chemotherapy nor any immunotherapy for HT and
were observed only. The mean age for these untreated
patients was 60 years (range: 48 ~ 71 years). All of these 6
patients had advanced stage disease (III/IV), were
treatment-exposed prior to HT, and most succumbed to
death via disease progression within months after the
diagnosis of HT.
There were two significant differences that were detected
between the SCT and no-SCT groups. First and expectedly,
patients not transplanted were older than those transplanted
(64 vs. 56 years, P = 0002). Secondly, a higher percentage of
patients receiving any transplant for HT were exposed to an
anthracycline-based regimen prior to HT compared to their
non-transplanted counterparts (60% vs. 38%, P = 003), and
a lower percentage of patients transplanted for HT were che-
motherapy-na€ıve compared to patients not transplanted for
HT (10% vs. 32%, P = 0005).
Outcomes
All patients. For all 118 patients, the 20 and 5-year OS was
68% (95% confidence interval [CI]: 59–76%) and 49% (95%
CI: 37–59), respectively, as depicted in the Kaplan–Meier
curve (Fig 1A). With a median follow-up time of 34 years
for all 118 patients, the median OS was 49 years. Of the 118
patients, 53 (45%) died: 58% of the no-SCT group, 30% of
the auto-SCT group, and 50% of the allo-SCT group. The
2-year OS for patients transplanted for HT (auto- and allo-
SCT) was 79% (95%CI: 69–89), while for the patients
not transplanted for HT, it was 53% (95%CI: 39–68), as
Table I. Clinical characteristics of all 118 patients.
Characteristic Number (N = 118)
Male, (%) 71 (60)
Median age at diagnosis of
indolent disease (range), years
55 (31 ~ 85)
Median age at diagnosis of
HT (range), years
59 (37 ~ 88)
Median time from diagnosis of
indolent NHL to HT,
months (range)
30 (6 ~ 184)
Ethnicity, (%)
Caucasian (non-Hispanic) 104 (88)
Hispanic 6 (5)
African-American (non-Hispanic) 4 (3)
Asian Pacific Island (non-Hispanic) 3 (3)
Unknown 1 (1)
Histology prior to transformation, (%)
Follicular 102 (86)
Grade 1 61 (52)
Grade 2 25 (21)
Grade 3a or 3 NOS 12 (10)
Grade NOS 4 (3)




Small Lymphocytic Lymphoma* 4 (3)
Therapy prior to HT, (%)
Observation only 23 (19)
Any treatment 95 (81)
Rituximab-based 83 (70)
Anthracycline-based 60 (51)
Median number of therapeutic
lines prior to HT (range)
1 (0 ~ 8)
Therapy for HT, (%)
Autologous SCT 50 (42)
Allogeneic SCT 18 (15)
No transplant 50 (42)
NHL, non-Hodgkin lymphoma; HT, histological transformation;
NOS, not otherwise specified; MALT, mucosa-associated lymphoid
tissue lymphoma; SCT, stem cell transplantation.
*All patients with Small Lymphocytic Lymphoma had lymphocyte
counts <50 9 109/l prior to HT.
Transformed NHL in the Rituximab Era
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illustrated in Fig 1B. Of the patients receiving a transplant,
the 2-year OS for the auto-SCT group was 83% (95%CI: 70–
91), and 65% (95%CI: 39–83) in the allo-SCT group. In the
auto-SCT group, there was no survival difference based on
Rituximab exposure prior to HT. Of the no-SCT patients,
those who were untreated prior to HT (no chemotherapy
nor monoclonal antibody therapy; n = 16) experienced a
superior survival compared to the no-SCT patients who were
treatment-exposed prior to HT (81% vs. 39%, P = 0003,
Fig 1C). Although there was no survival difference detected
between anthracycline exposure prior to HT when examining
the entire cohort of 118 patients, this was not the case in the
subgroup of non-transplanted patients. The non-transplanted
patients who were na€ıve to anthracyclines prior to HT expe-
rienced a superior survival compared to those who were
anthracycline-exposed (2-year OS of 61% vs. 38%, P = 005).
Patients aged ≤60 years. Of the patients aged ≤60 years
(n = 61), the 2- and 5-year OS was: 67% (95%CI: 53–77)
and 51% (95%CI: 34–65), respectively. For auto-SCT
patients aged ≤60 years (n = 24), the 2-year OS was 74%
(95%CI: 51–87). For allo-SCT patients aged ≤60 years
(n = 18), the 2-year OS was 65% (95%CI: 39–83). For
no-SCT patients aged ≤60 years (n = 19), the 2-year OS was
59% (95%CI: 32–78). These curves are depicted in the Kap-
lan-Meier curves in Fig 2A. In the non-transplanted younger
(aged ≤60 years) patients, the 2-year OS of the 6 patients
na€ıve to therapy prior to HT was superior to that of the 13
patients who were exposed to chemotherapy or Rituximab
prior to HT (100% vs. 35%, P = 003, Fig 2B). The 5-year
OS of these younger no-SCT patients that were treatment-
naive prior to HT was 80% (95% CI: 20–97%). Of the 6
non-transplanted younger patients that were treatment-na€ıve
prior to HT, two patients died (27 and 61 years after HT
respectively) and the other 4 have thus far not experienced
any other relapse or disease progression.
Cause of Death
Causes of death, stratified by treatment for HT, are outlined
in Table IV. Cause of death was due to disease progression
in 59% of the no-SCT patients, 60% of the auto-SCT
patients, and 44% of the allo-SCT patients. Death due to
treatment-related toxicity occurred in 17% of the no-SCT
Table II. Clinical characteristics of patients treated with stem cell transplantation for HT (n = 68).
Any SCT N = 68 Autologous SCT N = 50 Allogeneic SCT N = 18
Median Age at HT (range) 57 (37 ~ 78)* 60 (44 ~ 78) 52 (37 ~ 57)
Median months from diagnosis of indolent
NHL to HT (range)
1138 (37 ~ 184)** 1144 (6 ~ 184) 1138 (6 ~ 84)
Therapy Prior to HT, (%)
Observation only 7 (10)* 5 (10) 2 (11)
Rituximab 52 (77) 37 (74) 15 (83)
Anthracycline 41 (60)** 30 (60) 11 (61)
Median Number of Prior Therapeutic
Lines (range)
1 (0 ~ 8) 1 (0 ~ 4) 2 (0 ~ 8)
Median days from dx of HT to transplant 181 (63 ~ 1900) 174 (63 ~ 1900) 188 (75 ~ 565)
Disease status at SCT, (%)
Any response 51 (75) 39 (78) 12 (67)
Resistant 7 (10) 2 (4) 5 (28)
Unknown 10 (15) 9 (18) 1 (6)
NHL, non-Hodgkin lymphoma; HT, histological transformation; SCT, stem cell transplantation; Dx, diagnosis.
*Statistically significant difference between patients who obtained any SCT versus no SCT with P = 0002.
**Statistically significant difference between patients who obtained any SCT versus no SCT with P = 001.
Table III. Clinical characteristics of patients treated without trans-
plantation for HT (n = 50).
No transplant (N = 50)
Median age at HT (range), years 64 (38 ~ 88)
Median time from diagnosis of indolent
NHL to HT (months) (range)
21 (6 ~ 118)
Therapy Prior to HT (%)
Observation only 16 (32)
Rituximab 31 (62)
Anthracycline 19 (38)
Median Number of Prior Therapeutic
Lines (range)




R-CHOP variant 28 (56)




No therapy for Transformation, (%) 6 (12)
HT, histological transformation; R-CHOP, rituximab, cyclophospha-
mide, doxorubicin, vincristine, prednisolone.
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group, 7% of the auto-SCT group, and 44% of the allo-SCT
group. The median age of the 17% of no- SCT patients that
died of treatment-related mortality was 69 years (range:
59 ~ 80 years). Specific aetiologies for the treatment-related
toxicity for the allo-SCT group included fungal and bacterial
infections as well as hepatic veno-occlusive disease. Death
due to a secondary malignancy occurred in 2 patients in the
no-SCT group (both died from pancreatic cancer), a single
individual in the auto-SCT group (colon cancer), and a
single patient in the allo-SCT group (myelodysplastic
syndrome).
Discussion
Our study of 118 patients is the largest cohort of patients
with HT in the rituximab era. Importantly, we limited the
study to include only patients meeting stringent criteria for
histological transformation. We observed 3 main findings in
this study: (i) Outcomes for HT are improving, with higher
OS compared to historical data from the pre-rituximab era,
(ii) Autologous stem cell transplant continues to yield
favourable survival outcomes despite previous rituximab




Fig 1. Overall survival. (A) For all 118 patients, the 2- and 5-year
overall survival (OS) was 68% (95% confidence interval [CI]:
59–76%) and 49% (95%CI: 37–59%), respectively. (B) 2-year OS for
the non-stem cell transplantation (SCT) patients was 53% (95%CI:
39–68%) and for any SCT (auto-SCT and allo-SCT) group it was
79% (95%CI: 69–89%). (C) All non-transplanted patients (n = 50),
treatment prior to histological transformation (HT; n = 34) versus
no treatment prior to HT (n = 16). Among the no-SCT patients
(n = 50), those who were not exposed to chemotherapy nor mono-
clonal antibody therapy prior to HT (n = 16) experienced a superior
survival compared to that of the 34 patients who were treatment-
exposed prior to HT (81% vs. 39%, P = 0003).
(A)
(B)
Fig 2. Patients aged ≤60 years (n = 61). (A) Overall Survival (OS) in
years from histological transformation (HT) by treatment for HT.
For autologous stem cell transplantation (SCT) patients aged
≤60 years (n = 24), the 2-year OS was 74% (95%CI: 51–87%). For
allogeneic SCT patients aged ≤60 years (n = 18), the 2-year OS was
65% (95%CI: 39–83%). For no-SCT patients aged ≤60 years
(n = 19), 2-year OS was: 59% (95%CI: 32–78%). (B) Non-
transplanted patients aged ≤60 years (n = 19), no treatment prior to
HT (n = 6), versus treatment prior to HT (n = 13), (P = 003).
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specifically those that are na€ıve to any chemotherapy or
rituximab prior to HT, who experience a prolonged survival
without undergoing transplantation.
Although the underlying biology of transformation is not
fully understood, there is increasing data that HT may occur
by both divergent evolution from a common progenitor cell
and/or by a direct evolution from the indolent lymphoma
clone (Carlotti et al, 2009). Gene expression profiling (GEP)
of 20 paired samples of FL and HT performed by Davies
et al (2007) noted two pathways by which HT may evolve:
one that is similar in proliferation rate to the antecedent
FL and the other that has a higher proliferation rate and is
characterized by the presence of recognized oncogenic abnor-
malities. The acquisition of novel mutations via somatic hy-
permutations has also been implicated in the pathogenesis of
HT (Martinez-Climent et al, 2003; Rossi et al, 2006; Lawrie
et al, 2009). In addition, it has been suggested that the
tumour microenvironment may also play a critical role. In
one study, GEP signatures were performed on FL samples of
patients who developed HT later on and compared to those
who did not develop HT (Glas et al, 2007). The GEP of
patient samples who did not transform had a down-regula-
tion of the immune related genes, therefore implying that
HT may be mediated by an ‘immune signature.’ Rituximab
therapy may be altering the underlying biology of transfor-
mation by interfering with any of the aforementioned mech-
anisms, contributing to our observed favourable outcomes.
For example, Rituximab may affect genetic stability or
tumour proclivity for acquiring novel oncogenic mutations,
alter the tumour microenvironment, or change the regulation
of immune related genes.
In the current literature, data regarding outcomes for HT
are predominantly from the pre-Rituximab era. Studies from
the Rituximab era are only recently emerging. Reddy et al
(2012) studied patients who received either auto-SCT or
allo-SCT for early HT (within 1 year of FL). These patients
experienced a 5-year OS of 80%. This was compared to 15
patients in the same study who obtained SCT for late
transformation (>1 year of FL), whose 5-year OS was signifi-
cantly less at 34%. Recently, a Canadian study with 172
patients was published, where 22 patients were treated with
allo-SCT, 97 with auto-SCT, and 53 with rituximab-contain-
ing chemotherapy. The 5-year OS after HT was 46% for allo-
SCT, 55% for auto-SCT and 40% for no-SCT patients
obtaining rituximab-containing chemotherapy (Villa et al,
2013). However, this trial included patients treated since
1994, which was prior to Rituximab approval.
In this present study, patients who obtained autologous
SCT (n = 50) for HT experienced a 2-year OS of 83%, which
appears more favourable compared to not only the historical
controls from the pre-Rituximab era, but also to the
Canadian study as well. Although there are caveats to making
historical comparisons, similar survival data from the pre-
Rituximab era range between 40% and 74% (Foran et al,
1998; Friedberg et al, 1999; Chen et al, 2001; Williams et al,
2001; Andreadis et al, 2005; Sabloff et al, 2007; Ramadan
et al, 2008; Eide et al, 2011). There are a number of possible
explanations for improved outcomes for auto-SCT for the
treatment of HT in the Rituximab era, which include refine-
ment and increased adherence to supportive care, changing
eligibility for transplantation, and pretreatment rituximab
improving outcomes in ASCT. Interestingly, the outcome of
salvage therapy and auto-SCT for the treatment of de novo
DLBCL failing first-line therapy has been shown in the
CORAL (Collaborative Trial in Relapsed Aggressive Lym-
phoma) study (Gisselbrecht et al, 2010) to be inferior in
those exposed to Rituximab therapy. However, we did not
observe this phenomenon with transformed lymphoma in
our study, with improved survival seen with auto-SCT com-
pared to historical controls from the pre-Rituximab era. This
reinforces the concept that there is a distinct biology between
de novo DLBCL in first relapse and transformed DLBCL.
As expected in our registry study, there were distinct dif-
ferences between the group that was received transplant and
those not transplanted for HT. Transplanted patients tended
to be more heavily pre-treated, yet were also younger than
Table IV. Cause of death.
Total number of patients who died Allo-SCT (n = 9) Auto-SCT (n = 15) No-SCT (n = 29) All (n = 53)
Death due to disease progression, (%) 4 (44) 9 (60) 17 (59) 30 (57)
Treatment-related toxicity, (%) 4 (44) 1 (7) 5 (17) 10 (19)
Failure to recover blood counts – – 1
Fungaemia 1 – 1
Bacterial infection 2 – 2
Airway obstruction – – 1
Hepatic veno-occlusive disease 1 – –
Multi-organ failure post-transplant – 1 –







Motor Vehicle Accident, (%) 0 0 1 (3) 1 (2)
Unknown, (%) 0 (0) 4 (27) 4 (14) 8 (15)
SCT, stem cell transplantation; MDS, myelodysplastic symdrome.
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their non-transplanted counterparts. Therefore, outcome
comparisons between these groups cannot be made without
strong caveats. In an effort to minimize age as a confounding
factor for comparison, we performed a subgroup analysis
that was limited to patients aged ≤60 years. This analysis
yielded at least two major observations. First, given favour-
able OS for the entire ASCT group, auto-SCT should still be
considered for treatment of HT.
Another notable observation was that the 2- and 5-year
OS of the younger non-transplanted patients who were
na€ıve to any chemotherapy or monoclonal therapy prior to
HT were favourable, at 100% and 80% respectively. Disease
progression as a cause of death was similar between patients
who obtained auto-SCT (60%) and the non-transplanted
group (59%). These results suggest that younger patients
who are treatment-na€ıve prior to HT may still enjoy pro-
longed survival even without high-dose chemotherapy with
SCT. This is consistent with older data from Stanford in the
pre-rituximab era that demonstrated a superior OS in a
cohort of patients with transformed lymphoma, for patients
who were chemotherapy na€ıve at the time of transformation
compared with those patients who were previously treated
(Yuen et al, 1995). More recently, in a series of 60 patients
that transformed in the rituximab era, survival after HT was
also shown to be superior in patients who were initially
observed compared to those patients who were initially trea-
ted with chemotherapy for their indolent disease (Link et al,
2012). Although radioimmunotherapy was approved in the
United States for treatment of HT during our study
(Gordon et al, 2004; Fisher et al, 2005b; Wondergem et al,
2012), and recent data suggests lenalidomide has substantial
single-agent activity in transformed lymphoma (Czuczman
et al, 2011), only three patients in our study were treated
with radioimmunotherapy and two patients were treated
with lenalidomide at transformation. Therefore, the impact
of these novel regimens cannot be ascertained in our data-
base.
Existing data regarding the use of allogeneic transplanta-
tion for HT are also limited, with the number of patients
in these series ranging between 5 and 25 patients. In one
series of 16 patients who underwent alloSCT for HT, there
were 8 deaths related to transplant complications, 4 patients
died of disease relapse, and the remaining 4 patients were
alive and disease-free at <2 years post-SCT (Doocey et al,
2005). In another study of 16 patients with HT undergoing
reduced-intensity conditioning (RIC) with allo-SCT, the 3-
year OS was 21% (Rezvani et al, 2008), and in a series of
18 patients receiving RIC allo-SCT, the 4-year OS was 60%
(Thomson et al, 2009). In our study, we report the OS of
18 patients undergoing allogeneic transplant for the treat-
ment of HT in the Rituximab era. These patients experi-
enced a 2-year OS of 65%. Similar to the other studies,
cause of death in our study for the patients after an allo-
SCT were mostly attributed to either disease progression
(44%) or transplant-related mortality (44%), which included
fungal and bacterial infections as well as hepatic veno-occlu-
sive disease.
We acknowledge that comparisons between the various
subgroups in this study as well as to historical controls can-
not be adequately validated without a randomized controlled
trial. However, it is unlikely that a randomized trial evaluat-
ing transplantation versus no transplantation will ever be
completed due to accrual barriers. An intergroup study
attempting to evaluate the role of radioimmunotherapy in
HT closed after 3 years due to lack of accrual. Nevertheless,
from our data, it appears that several treatment approaches
individualized to patient factors are efficacious. Future
studies need to explore the impact of molecular and immu-
nological factors on treatment outcomes. For example, it is
clear from studies in DLBCL that double hit features
(BCL2- and MYC-positive disease) portend very poor out-
comes (Friedberg, 2012); this is likely to be the case in HT
as well.
In conclusion, compared with historical series, the
natural history of histologically-defined HT appears more
favourable in our multicentre, prospective cohort in the
rituximab era. Long-term survival is seen with a variety of
treatment strategies. In particular, patients who are therapy-
na€ıve prior to transformation may experience favourable
outcomes with Rituximab-containing therapy alone without
transplant. Future studies should evaluate predictive biologi-
cal factors and validate our results to determine which
patients may benefit from a conservative approach to treat-
ment of HT. We believe that the present study serves as an
important benchmark for future trials of novel approaches
for HT.
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